Bank OZK (OZK): Among Cheap Rising Stocks to Buy Right Now
We recently published a list of the 10 Cheap Rising Stocks to Buy Right Now. In this article, we will look at where Bank OZK (NASDAQ:OZK) stands against other cheap rising stocks in which to invest.
On May 2, US stocks notched their longest winning streak since 2004 as the United States and China signaled a willingness to have trade talks. The broad market index rose 1.47%, which helped it erase the losses since the Trump administration announced reciprocal tariffs on April 2.
READ ALSO: ChatGPT Stock Advice: Top 12 Stock Recommendations and 11 Worst Performing Stocks in S&P 500 So Far in 2025.
Trump told Time magazine on April 22 that his administration was engaged with China on striking a tariff deal. The US president also said he expects announcements on many other trade deals to be made over the next three to four weeks.
During an interview with NBC on May 2, the US President stated that tariffs on Chinese imports will eventually be lowered:
At some point, I'm going to lower them because otherwise, you could never do business with them. They want to do business very much … their economy is collapsing.'
Jay Hatfield, founder and chief investment officer of InfraCap, believes the worst of the uncertainty around tariffs is over. He shared the following remarks while talking to CNBC:
'The confusion about whether there's really talks going on with China or not took some steam out of the market. Our view is that we've reached peak tariff tantrum and so it's likely to be more positive than negative.'
A spokesperson for China's Commerce Ministry has said the country is currently assessing proposals shared by Washington to begin trade negotiations. Analysts view the statement as a subtle shift in tone from Beijing that could potentially open the door for talks on tariffs.
The stock market has also received a boost from the latest jobs data shared by the Bureau of Labor Statistics. The American economy added 177,000 new jobs in April. While this was slightly down from 185,000 jobs in March, the gain was still stronger than the average pace of monthly job growth in the last three months, which reflected the resilience of the US job market.
An iconic skyline of a major city, the towering buildings display the strength of the company's regional banking success.
For this article, we sifted through screeners to identify stocks with returns of 10% or more over the past 30 days, a forward P/E ratio of less than 15, a trailing P/E ratio of less than 15, and a P/B ratio of under 1. From there, we picked the 10 stocks with the lowest forward P/E ratio and ranked them in descending order. All data is as of the close of business on May 5, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
30-day returns: 15.56%
Forward P/E ratio: 7.48
Bank OZK (NASDAQ:OZK) is a regional bank with operations in more than 240 offices across nine states. The company delivers various innovative financial solutions to clients, including savings, checking, loans, mortgages, treasury management, credit cards, merchant services, trust and estate services, and more.
During its recent earnings call on April 16, Bank OZK (NASDAQ:OZK) reported a net income of $167.9 million for the first quarter of fiscal 2025, decreasing 2.1% compared to the prior year's period. Diluted earnings per share were posted at $1.47. While this was also down 2.6% year-over-year, the figure beat analysts' estimates by 5 cents, representing an earnings surprise of 3.52%.
Bank OZK (NASDAQ:OZK) has surpassed analysts' EPS consensus in the last four quarters. In Q4 2024, the company produced earnings of $1.56 per share, against forecasts of $1.45 per share. The stock has surged since the latest earnings call, enabling OZK to have monthly returns of over 15%, making it one of the cheap rising stocks to buy right now.
However, Stephens & Co., on April 21, cut Bank OZK (NASDAQ:OZK)'s price target from $59 to $54 per share, as the bank's guidance for fiscal 2025 largely remained unchanged. Overall, Wall Street analysts have a consensus Hold rating for the stock, with an average share price upside potential of 12.4%.
Overall, OZK ranks 9th among the cheap rising stocks to buy right now. While we acknowledge the potential of OZK as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than OZK but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ('Gyre') (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A ('ETA') receptor antagonist, for the treatment of pulmonary arterial hypertension ('PAH').This milestone marks Gyre's entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options. PAH is recognized in China's National Rare Disease Catalog, underscoring its significance in public health. According to Frost & Sullivan, China's PAH market was valued at $370 million in 2023 and is projected to grow to $480 million by 2031.F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this pathway, F230 is designed to reduce pulmonary vascular remodeling and lower pulmonary pressure, key contributors to PAH Phase 1 trial is designed to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. The trial represents the latest expansion of Gyre's fibrosis-first strategy beyond the liver, leveraging a robust clinical development platform and commercial infrastructure in China.F230 joins Gyre's pipeline alongside lead candidate Hydronidone (F351), which met the primary endpoint in a pivotal Phase 3 trial for CHB-fibrosis. A New Drug Application ('NDA') submission to China's National Medical Products Administration ('NMPA') is planned for the third quarter of 2025, and a pre-IND meeting with the U.S. Food and Drug Administration is being planned for an expected Phase 2 trial in metabolic dysfunction-associated steatohepatitis ('MASH') Gyre TherapeuticsGyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the U.S. Gyre's strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People's Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and StatementsThis press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning the expectations regarding Gyre's research and development efforts and timing of expected clinical trials, including an NDA submission to the NMPA for F351, the expected clinical benefits of F230 and expectations regarding interactions with regulators. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'objective,' 'intend,' 'should,' 'could,' 'can,' 'would,' 'expect,' 'believe,' 'design,' 'estimate,' 'predict,' 'potential,' 'plan' or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre's ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre's capital resources and its ability to raise additional capital. Additional risks and factors are identified under 'Risk Factors' in Gyre's Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings Gyre may make with the SEC. Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by Contact:David ZhangGyre in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
BlackRock, Goldman Scale Up Tax Trades in $3 Trillion SMA Boom
(Bloomberg) -- This year's stock market turbulence has punished ordinary investors. But for the wealthy, it's opened up fresh opportunities to convert equity swings into tax breaks — fueling a growing Wall Street business that turns volatility into a financial advantage. Trump Said He Fired the National Portrait Gallery Director. She's Still There. NYC Mayoral Candidates All Agree on Building More Housing. But Where? Senator Calls for Closing Troubled ICE Detention Facility in New Mexico California Pitches Emergency Loans for LA, Local Transit Systems BlackRock Inc., Goldman Sachs Group Inc. and Morgan Stanley are among firms scaling up a strategy known as tax-loss harvesting, typically offered through customized portfolios called separately managed accounts. When markets drop, managers sell stocks trading below their purchase price to realize losses. Those losses offset gains elsewhere in a portfolio, reducing clients' tax liabilities while maintaining overall portfolio exposure. The approach allows investors to shrink their current-year IRS bills while deferring capital gains into the future. In April's selloff, for example, a manager could dump Home Depot Inc. and rotate into Lowe's Cos Inc., maintaining sector exposure while staying inside tax rules. Once a boutique service reserved only for the ultra-rich, investment firms are repackaging market turbulence as a fiscal opportunity, with automated trading programs scanning portfolios daily as equity conditions shift. With fee pressure eroding revenue in traditional asset management, Wall Street is leaning more heavily on tax-optimization trades to differentiate offerings, retain clients and defend margins in a competitive marketplace. 'There is just inherently going to be more volatility in the system,' said Scott Smith, senior director at industry consultant Cerulli Associates. 'With trade policies, tariffs, taxes, everything is on the table. There is no assumption of what the future looks.' In one particularly active stretch during April's selloff, BlackRock's Aperio, a platform for personalized portfolios, executed more than $18 billion in trades. That generated $700 million in realized losses that can be used to offset taxable gains elsewhere in client portfolios, or so-called tax-loss harvesting. That equated to roughly $5 to $7 in losses realized for every $100 traded that month. 'We monitor daily. We look at losses and high-cash positions. We balance harvesting with managing tracking error,' said Ran Leshem, who oversees BlackRock's separately managed account business, now managing $220 billion. 'Our goal is to be the market leader in SMAs.' Still, even as this year's selling frenzy created opportunities, the equity rebound that followed highlights a trade-off: while the approach can lower future tax bills, it also locks in losses that may prove costly if markets quickly recover, making the ultimate payoff difficult to measure in real time. Regardless, the opportunities are only growing. Direct indexing, where investors hold individual stocks directly rather than through pooled funds, has become the backbone of this tax-optimization machine. With the SMA market expected to grow from $3 trillion to $5 trillion by 2027, firms are layering on increasingly complex techniques to compete, pitched as added-value services. Tax-loss harvesting is only one lever. Advisors also optimize dividend timing, gain deferrals, charitable gifting and jurisdictional overlays in an attempt to juice after-tax portfolio performance. 'Risk management and tax management go hand in hand,' said Monali Vora, global head of wealth investment solutions at Goldman Sachs Asset Management. 'You can't do one without the other.' Aperio's long-short tax-aware strategies, launched in 2023, amplify gross exposure — boosting the number of positions that can generate harvestable losses, while keeping market exposure roughly the same. About 7% of April's realized losses came from these strategies. While still a small share of overall assets, it's part of the firm's expanding business. Managing tracking error, or how closely a portfolio tracks its benchmark, remains a challenge. The IRS wash-sale rule bars investors from buying back the same, or substantially identical, securities over a specified timeframe. Firms navigate these constraints by swapping into correlated securities. Selling Moderna Inc. and buying Pfizer Inc. is straightforward; replacing a giant like Apple Inc. requires more complex substitutes. 'Clients are seeking alpha, downside protection and more tax-loss harvesting potential for both ETF and stock positions,' Leshem said. 'But with that comes the tug of war between harvesting and maintaining tracking error.' At Dimensional Fund Advisors LP, the approach is different. Instead of mirroring an index, the Texas-based firm uses broad diversification across thousands of stocks to reduce wash-sale risk, reallocating proceeds toward securities with higher expected returns based on their quant model. 'We can keep the profile of the account but take advantage of tax opportunity,' said Savina Rizova, co-chief investment officer and global head of research. Dimensional, which lowered its account minimum to $500,000 in 2021, harvested $20 million in net losses across about 1,400 accounts in April — averaging $16,700 in losses per $1 million invested. Parametric, Morgan Stanley's direct indexing arm, strikes a more cautious tone. 'Tax-loss harvesting is one layer of customization, but there are many others,' said co-president and CIO Tom Lee. 'For most institutions, tax management isn't their focus.' At the height of April's volatility, Parametric harvested $620 million in losses, generating around $230 million in potential tax benefits. That same month, Parametric also introduced an offering with a $25,000 minimum investment, part of a broader push to open direct-indexing features to smaller accounts and widen the client base for tax-managed SMAs. Quant hedge funds such as AQR Capital Management are also in tax-optimization arena, applying long-short structures aimed at maximizing harvestable losses while managing exposure drift. As competition heats up, Goldman Sachs Asset Management is pushing into new customization features to expand its tax-optimized platform, such as introducing capabilities to migrate equity ETFs into SMA portfolios. The firm has also ramped up its engineering staff to scale automation and global execution as tax-optimized services become increasingly industrialized. While tax-loss harvesting can reduce tax bills, research shows the biggest benefits tend to accrue to wealthier investors with large taxable portfolios and steady capital gains to offset. As such, for investors able to access these platforms, the appeal is simple. 'There is an awareness among investors that it's not what you make, it's what you keep,' said Parametric's Lee. 'Taxes represent a headwind for investors to the extent they have to realize gains in taxable accounts. You can take advantage of volatility when it comes.' --With assistance from Justina Lee and Lu Wang. New Grads Join Worst Entry-Level Job Market in Years The SEC Pinned Its Hack on a Few Hapless Day Traders. The Full Story Is Far More Troubling What America's Pizza Economy Is Telling Us About the Real One Cavs Owner Dan Gilbert Wants to Donate His Billions—and Walk Again American Mid: Hampton Inn's Good-Enough Formula for World Domination ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Journals
12 minutes ago
- Business Journals
Daily Digest: End of an era at Fisherman's Wharf, Scale AI eyes record funding from Meta
Happy Monday, Bay Area. Tensions remain high in Los Angeles as protests against Immigration and Customs Enforcement took over the city this weekend, with demonstrators clashing with law enforcement as President Trump deployed 2,000 members of the National Guard to "address the lawlessness." The state of California will file a lawsuit on Monday challenging President Trump's use of the National Guard, Gov. Gavin Newsom stated on social media. Trump suggested Newsom should be arrested over his response. Protests also broke out in downtown San Francisco on Sunday with 60 arrests made, the Chronicle reports. Meanwhile in transportation, Alphabet-owned Waymo has suspended service of its ride-hailing service in downtown Los Angeles after some of its vehicles were set on fire during protests. Closer to home here in the city, S.F.'s first all-women's sports bar — Rikki's — is opening on Wednesday at 2223 Market St., an upper Market location that has seen a number of short-lived concepts over the past few years. And finally, the San Francisco-Marin Food Bank has announced the closure of all its farmers market-style pantries by June 30, as well as reductions to its home delivery service and staff. ABC7 also reports that 13 pantries closed for good Friday after the money ran out. Here's the rest of the local business news to start your week. GET TO KNOW YOUR CITY Find Local Events Near You Connect with a community of local professionals. Explore All Events Alioto's to be torn down at Fisherman's Wharf Alioto's Restaurant, the longtime waterfront seafood spot at Fisherman's Wharf that closed down in 2020, will be demolished and replaced by a new public plaza as part of a $10 million plan by the Port of San Francisco to reimagine the historic heart of Fisherman's Wharf, the Chronicle reports. Knocking down Alioto's and building a plaza are at the heart of a package of wharf upgrades, of which the port expects to complete the first phase by next year. expand The three-story, 11,000-square-foot Alioto's structure at Fisherman's Wharf will be torn down. Todd Johnson | San Francisco Business Times Business owners expect disruptions as wine and spirits distributor pulls out of California One of the nation's largest wine and spirits distributors recently announced it's pulling out of California, a move expected disrupt restaurant and bar operators and retailers statewide. Republic National Distributing Company, which operates in 39 states across the U.S., announced last week that it will exit the California market, effective Sept. 2, the Sacramento Business Journal reports. RNDC's remaining portfolio of wine and spirit brands will now be on the hunt for new distributors in California in order for their products to remain on shelves and in bars, according to local business leaders. Wild pigs are going hog wild in Santa Clara. Now authorities are going "Full Boar" Wild pigs are on the rise in Santa Clara County and have led to an uptick in property damage. As a result, the Santa Clara Valley Open Space Authority, an agency in San Jose that has preserved 30,000 acres of land as outdoor public space, last month approved spending $243,000 to hire a contractor, Full Boar Trapping and Wildlife Control, based in Contra Costa County, to trap and shoot wild pigs over the next three years on its properties, the Mercury News reports. The report states that Russian boars were first introduced to the region in 1924 when eccentric Canadian millionaire George Gordon Moore purchased Rancho San Carlos, a 22,000-acre ranch in Carmel Valley. Some escaped and bred with the local pigs first brought by the Spanish in 1769. The pigs grow sharp tusks, weigh 250 pounds or more and have been known to attack hikers. Sign up for the Business Times' free morning and afternoon daily newsletters to receive the latest business news driving change in San Francisco. Download the free San Francisco Business Times app for breaking news alerts on your phone. People on the Move The National Venture Capital Association has named Vineeta Agarwala, general partner at A16z, as chair of the NVCA board of directors. In addition, Alex Doll of Ten Eleven Ventures has joined the NVCA board of directors. Mobilicom Limited (Nasdaq: MOB), a Palo Alto-based provider of cybersecurity and solutions for drones and robotics, named Guy Givoni to its board of directors. Givoni previously served on Mobilicom's advisory board from 2017 through 2023. Funding Watch San Francisco-based Scale AI is in talks to raise more than $10 billion from Meta, Bloomberg reports. The financing could exceed $10 billion in value, anonymous sources said, making it one of the largest private funding events of all time. The terms of the deal are not finalized and could still change and representatives for Scale AI and Meta declined to comment. The startup was last valued at about $14 billion in 2024, in a funding round that included backing from Meta and Microsoft. expand Alexandr Wang, co-founder and CEO of Scale AI David Paul Morris/Bloomberg via Getty Images IPO Watch In case you missed it, check out these seven questions Senior Reporter Ron Leuty last week got to ask Sean Duffy, the CEO of newly public Omada Health. Final thought … Sometimes it's the small things that people in industry do that have the biggest impact. For example, making the home computer user-friendly. That was the genius of Bill Atkinson, the Apple designer who created the software pioneered by the company's Lisa and Macintosh computers that made the machines accessible to millions of users without specialized skills, the New York Times reports. RIP to Atkinson, who died on Thursday at his home in Portola Valley at the age of 74. DOWNLOAD the free SFBT app for breaking news alerts on your phone.
